To Present on AVA6000 and AVA6103 at ESMO 2026

Avacta Group PLC

14 October 2026

 

Avacta Group plc

("Avacta" or the "Company")

Avacta to Present Progression Free Survival Data on Faridoxorubicin (AVA6000) and the FOCUS-01 (AVA6103) Trial Design at the ESMO 2026 Congress

LONDON and PHILADELPHIA - October 14, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, today announces the Company will present the most recent data analysis from the ongoing Phase 1a trial of Faridoxorubicin (AVA6000) and the design of the FOCUS-01 trial of FAP-Exd (AVA6103) in two poster presentations at the European Society for Medical Oncology (ESMO) 2026 Congress, to be held in Madrid from October 23-27, 2026.

A presentation on October 26, 2026 will include the progression-free survival (PFS) data in patients with salivary gland cancer (SGC) as well as FAPI-PET imaging data from this expansion cohort from the ongoing Phase 1a/1b trial of Faridoxorubicin (AVA6000) in patients with Fibroblast Activation Protein (FAP)-positive solid tumors 

A second presentation featuring the design of the Phase 1 FOCUS-01 trial will include updated preclinical data on AVA6103.

Details of the presentations

A Phase 1a/1b trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with salivary gland cancers  

Authors: Renata Ferrarotto, Robert Metcalf, Steph A. Pang, William D. Tap, et. al, Alan L. Ho       

Poster number: 1549P

Time: Monday October 26, 12:00-12:45pm CET

A phase I trial of FAP-Exd (AVA6103), a Fibroblast Activation Protein (FAP)-enabled pre|CISION® peptide-drug conjugate delivering sustained tumor microenvironment (TME) release of exatecan in patients with FAP-positive solid tumors

Authors: Alexander I. Spira, Nehal J. Lakhani, Judy S. Wang, Muhammad R. Khawaja, Ruairidh Edwards, Karen Campbell, Curtis Rink, Christiana Nikolova, David Liebowitz

Poster number: 1134eTiP

Time: e-Poster TIP Session

-Ends-

For further information from Avacta, please contact:

Avacta Group plc Christina Coughlin, Chief Executive Officer	https://avacta.com/ via Cohesion Bureau
Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance	www.strandhanson.co.uk
Zeus (Broker) James Hornigold / George Duxberry (Investment Banking) Dominic King / Alex Bartram (Corporate Broking)	www.zeuscapital.co.uk
Cohesion Bureau Communications / Media / Investors Chris Maggos	[e-mail]

About Avacta - https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies.

Our pre|CISION® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre|CISION® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer.

About FAP-Exd (AVA6103)

AVA6103 is the second clinical candidate and is the first asset in the pipeline based on the Next Generation innovative pre|CISION^® controlled release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure. AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload. 

 

END